ImmunGene Inc., a biotechnology company, focuses on the discovery and development of monoclonal antibody-based therapeutics to treat cancer, autoimmune disorders, and other diseases. Its products pipeline includes IGN002, which is targeted on non-Hodgkin lymphoma and other B cell driven hematologic malignancies; IGN001 that focuses on the treatment of breast cancer and other malignancies; IGN003, a monoclonal antibody directed towards a validated multiple myeloma target; IGN004, which is targeted on multiple solid tumors and melanomas; IGN005 that is targeted on AML and other leukemias; and IGN006, which is targeted on multiple solid tumors. ImmunGene Inc. also has a joint venture, Valor Biotherapeutics, LLC, with Caliber Biotherapeutics, LLC that focuses on the clinical development and commercialization of monoclonal antibody-interferon (mAb-IFN) fusion protein therapeutics targeting cancers.
